Revolution Medicines

Revolution Medicines

Yahoo Finance • 6 days ago

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Corporate Affairs - Ryan AsayChairman and Chief Executive Officer - Mark GoldsmithChief Development Officer - Alan San... Full story

Yahoo Finance • 6 days ago

Why Revolution Medicines May Be Big Pharma’s Next Takeover Target

Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure... Full story

Yahoo Finance • 6 days ago

Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors, alongside a regional licensing deal granti... Full story

Yahoo Finance • 14 days ago

Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48%... Full story

Yahoo Finance • 15 days ago

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines. Continue Reading... Full story

Yahoo Finance • 16 days ago

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock

Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to the stock by buying 316,000 shares of Re... Full story

Yahoo Finance • 17 days ago

Vanguard VONG vs VBK: Is a Small Cap ETF the Better Buy Over a Large Cap Fund in 2026?

Vanguard Russell 1000 Growth ETF (NASDAQ:VONG) offers heavy concentration in mega-cap technology leaders, while Vanguard Morningstar Small-Cap Growth ETF (NYSEMKT:VBK) provides a diversified mix of smaller growth companies at a slightly lo... Full story

Yahoo Finance • 20 days ago

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will... Full story

Yahoo Finance • last month

Which Is the Better Small-Cap ETF, Schwab's SCHA or iShares' IJR?

While the iShares Core S&P Small-Cap ETF (NYSEMKT:IJR) offers concentrated exposure to profitable small-caps, the Schwab U.S. Small-Cap ETF (NYSEMKT:SCHA) provides a broader, more tech-leaning portfolio with a lower expense ratio. Small-c... Full story

Yahoo Finance • last month

SCHA vs. SPSM: Which Small-Cap ETF Is the Better Buy?

Key Points The Schwab U.S. Small-Cap ETF (SCHA) holds nearly three times as many positions as the State Street SPDR Portfolio S&P 600 Small Cap ETF (SPSM). Both ETFs carry identical 0.03% expense ratios, but SPSM has a higher dividend yie... Full story

Yahoo Finance • last month

RVMD Reports Antitumor Activity From Phase 1/2 Zoldonrasib Trials In Pancreatic Cancer

(RTTNews) - Revolution Medicines, Inc. (RVMD), late-stage clinical oncology company, on Thursday announced results from two Phase 1/2 clinical trial evaluating zoldonrasib-based combination regimens for the treatment of RAS G12D metastatic... Full story

Yahoo Finance • last month

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?

Revolution Medicines (NASDAQ: RVMD) spent most of its history as a publicly traded company -- that's since 2020 -- trading for less than $50 a share. The company offers a new approach to oncology treatment, aiming for targets once thought... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.

Key Points Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year. Despite a strong outlook, the stock still looks... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines – ERAS

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).   Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 2 months ago

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placi... Full story

Yahoo Finance • 2 months ago

SCHA vs. ISCB: Which Small-Cap ETF Is the Better Buy for Investors in 2026?

Investors seeking small-cap exposure often prioritize low fees and broad diversification. Both the Schwab U.S. Small-Cap ETF (NYSEMKT:SCHA) and the iShares Morningstar Small-Cap ETF (NYSEMKT:ISCB) track hundreds of smaller U.S. companies,... Full story

Yahoo Finance • 2 months ago

Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best hot stocks to buy for June. On June 8, RBC Capital reiterated an Outperform rating on Revolution Medicines Inc. (NASDAQ:RVMD) and a $182 price target.Pancreatic Cancer Drug Milesto... Full story

Yahoo Finance • 2 months ago

Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?

Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorpora... Full story

Yahoo Finance • 2 months ago

Can Revolution Medicines Be a Game-Changer Stock?

Key Points Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs. It is a likely target for a buyout by lar... Full story

Yahoo Finance • 2 months ago

Top Midday Gainers

Tango Therapeutics' (TNGX) initial results from a phase 1/2 trial of vopimetostat in combination wit PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story